Floatz logo

National Cancer Institute -4650, A Messenger Ribonucleic Acid -Based, Personalized Cancer Vaccine

Genitourinary Cancer

National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Genitourinary Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
Spanish Oncology Genito-Urinary Group
Phase 2B
Tadalafil
Regina Elena Cancer Institute
Phase 3B
Atezolizumab
British Columbia Cancer Agency
Phase 2B
Ipilimumab
Dana-Farber Cancer Institute
Phase 2B
Riluzole
University of California, Irvine
Phase 2CCC

View all 31 →

Same molecule, other indications

National Cancer Institute -4650, A Messenger Ribonucleic Acid -Based, Personalized Cancer Vaccine is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
digestive system cancerDormant
CC
Indicative ·
45 / 100
View asset →
melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →